Shenzhen Chipscreen Biosciences Wins Approval for NW001 Phase 1 Cancer Trial
Chinese health regulators have granted Investigational New Drug clearance to Shenzhen Chipscreen Biosciences Co., Ltd. (SSE:688321) to begin a Phase 1 clinical trial for NW001. The early-stage trial will evaluate the experimental treatment in China among patients diagnosed with advanced tumors. Shares of the company last traded down 0.59% at 21.8 CNY.
The drug candidate, NW001, is an antibody conjugate designed to target PD-L1 with an HDACi payload. It aims to reduce systemic exposure and expand therapeutic potential to tumors that do not respond to existing PD-1 or PD-L1 therapies. The trial approval marks a key step in broadening the company's immuno-oncology portfolio beyond its approved drug, chidamide.
Investors and researchers will monitor the Phase 1 and subsequent Phase 1b trials for initial safety data and early signs of antitumor effectiveness. Demonstrating a favorable safety profile and clinical activity will be crucial for the company to attract future partnerships, secure funding, or support pipeline valuation.
Key points
- Shenzhen Chipscreen Biosciences received IND approval in China for a Phase 1 trial of NW001 in advanced tumors.
- NW001 combines a PD-L1-targeting antibody with an HDACi payload to improve tolerability and target resistant tumors.
- The milestone expands the company's immuno-oncology pipeline beyond its approved drug chidamide.
- Future clinical progress will focus on establishing safety and preliminary antitumor activity in early testing.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is NW001 developed by Shenzhen Chipscreen Biosciences?
NW001 is a PD-L1-targeted antibody conjugate with an HDACi payload designed to treat advanced tumors while lowering systemic exposure.
What approval did Shenzhen Chipscreen Biosciences receive for NW001?
The company received Investigational New Drug approval in China to launch a Phase 1 clinical trial in patients with advanced tumors.
What is the next step for NW001's development?
Researchers will evaluate the safety profile and preliminary antitumor activity of NW001 during Phase 1 and Phase 1b clinical trials.